Now I have a thorough understanding of the paper. Let me produce the final consolidated review.

## Summary

This paper introduces *inference set design*, a framework for hybrid biological screens where an active learner sequentially acquires labels for the hardest-to-predict examples in a finite target set, thereby simplifying the remaining inference set and achieving high system accuracy with fewer experiments. The authors formalize the problem, propose a confidence-based acquisition strategy with a probabilistic stopping criterion (Lemma 1 + KL-divergence bound), and demonstrate the mechanism across MNIST variants, QM9 molecular data, and a large-scale proprietary phenomics assay.

---

## Strengths

1. **Clean formalization and direct causal evidence of the mechanism.** The paper clearly defines the hybrid-screen problem (Eq. 1–2) and then provides direct evidence that gains come from *pruning hard examples* rather than from improved generalization. The MNIST label-noise experiment (Fig. 2c) is the strongest demonstration: the active agent systematically acquires shuffled-label digits first, its batch accuracy jumps after those are removed, and the test-set accuracy plateaus identically for active and random agents. This cleanly separates inference-set design from generalization-driven active learning.

2. **Systematic diagnosis across multiple sources of difficulty.** The paper tests three distinct sources of heterogeneity—partial observability (cropped MNIST), labeling noise (shuffled digits), and inherent difficulty (MNIST and QM9)—in separate controlled experiments (Figs. 2–3). The mechanism holds across all cases. The additional analysis tracking acquisition of "hard-to-predict" molecules in QM9 (Fig. 3c) confirms the mechanism operates in a chemically diverse domain, not just images.

3. **Large-scale real-world validation.** The proprietary phenomics dataset (~100 k compounds, ~5 k genes, ~2,000× larger relationship matrix than RxRx3) provides a convincing industrial-scale demonstration (Fig. 4). The active agent reaches 98% system accuracy after ~80% acquisition, while random lags behind at ~85–90%. This scale and practical relevance far exceeds typical active-learning benchmarks.

4. **Principled stopping criterion with theoretical grounding.** The derivation of a conservative lower bound on inference-set accuracy (Lemma 1 under weak calibration) and the KL-divergence-based concentration bound (Eq. 4) is theoretically sound and goes beyond the heuristic stopping rules common in the drug-discovery active-learning literature.

---

## Weaknesses

### Fatal
None.

### Major

1. **The stopping criterion is theoretically derived but not empirically validated.** The paper claims a probabilistic stopping rule (Eq. 4) that guarantees system accuracy ≥ γ with probability at least 1 – δ, yet provides no experimental evaluation of whether this guarantee holds in practice. Section 3.4 is titled "Empirical validation of weak calibration and stopping criterion" but only validates the weak-calibration assumption (monotonic confidence ordering on QM9). There is no analysis of: whether the KL-based lower bound α_t is actually conservative for μ_inf^t, how often the system accuracy at the estimated τ exceeds γ, whether the criterion stops too early (and fails the guarantee) or too late (and wastes experiments), or how the choice of δ affects behavior. Since the stopping criterion is a central algorithmic contribution and the paper's title emphasizes "efficient" data acquisition, omitting this evaluation is a significant evidential gap. *Why it matters*: The paper promises a "provably" reliable automatic stopping procedure, but readers cannot assess whether the proof translates into practice.

2. **The RxRx3 dataset is described at length but no results are presented.** Section 3.3 devotes a paragraph to setting up an experiment on the public RxRx3 dataset (data preprocessing, similarity matrix construction, thresholding), then transitions to a proprietary dataset with the opaque statement "We believe this is due to high complexity of biological relationships and limited size of the inference set" — where "this" has no antecedent in the text because no RxRx3 result was shown. The reader cannot determine whether the experiment was run and failed, or whether the description is purely background. This breaks the narrative flow of "a real-world case study" and undermines the empirical narrative. *Why it matters*: A failure case would be informative and help define the method's scope; an absent result leaves an unexplained hole in the evaluation.

### Minor

3. **Weak-calibration assumption validated only on QM9.** The calibration analysis (Fig. 5) convincingly shows that the model maintains monotonic confidence ordering on QM9, but this is assessed for only one dataset and one acquisition function (LC). The claim that the stopping criterion is valid rests on this assumption holding across settings; the paper would benefit from similar analysis on MNIST and the proprietary dataset (where available).

4. **Gains on the proprietary biological assay are smaller and underexplained.** The active agent reaches ~98% system accuracy at ~80% acquisition versus random at ~85–90% (Fig. 4). While practically meaningful, the gap is notably smaller than in MNIST or QM9. The paper does not discuss why—possible reasons include high base accuracy, low variance in example difficulty, or correlation across compound–gene pairs—which would help practitioners understand when inference set design is most impactful.

5. **No statistical significance testing.** The paper reports means and standard errors over 3 seeds but does not test whether the active agent's improvements over random are significant, especially important on the proprietary dataset where gains are modest.

### Trivial

- None.

---

## Nice-to-Haves

- An explicit analysis of how the stopping criterion's conservatism (choice of δ, batch size N_b) affects the tradeoff between early stopping and guarantee violation.
- A discussion of additional limitations: the weak-calibration assumption may fail early in acquisition when the model is poorly calibrated; retraining from scratch at every step is computationally expensive; the method assumes the target set is fixed and known a priori.
- Validation of weak calibration on at least one additional dataset beyond QM9.

---

## Removed Points

These points are flagged to be removed; treat them with caution.

1. **"Lemma 1 proof is relegated to the appendix"** — This is standard practice across ML/CS conferences and does not constitute a weakness.
2. **"Heuristic orderings in QM9 are not standard active-learning baselines"** — The paper does not claim they are; it compares against commonly used heuristic screening orders (molecule size, SA-score, diversity sampling), which is a valid practical comparison. The critic's framing misreads the paper's intent.
3. **"The paper should discuss why the proprietary gains are modest"** — Already present as a Minor weakness above; this is not a separate point but the same observation moved to the correct tier.
4. **"Missing limitations discussion about computational cost, calibration early in acquisition, fixed target set"** — Fair as a nice-to-have suggestion, not a weakness. Moved to Nice-to-Haves.
5. **"Weak-calibration assumption may be violated in practice (early acquisition)"** — The paper already partially addresses this via the QM9 calibration analysis, and the concern is noted in the Minor weakness list (point 3). The critic's framing is more speculative than concrete.

---

## Novel Insights

None beyond the paper's own contributions. The primary novel insight from the review process is that the paper's conceptual contribution (inference set design) is well-supported, but its practical algorithmic claim (the stopping criterion) requires direct empirical validation that is currently absent.

---

## Suggestions

1. **Validate the stopping criterion empirically.** For each acquisition step, compute the KL-based lower bound α_t on μ_inf^t and compare it against the actual inference-set accuracy measured at that step (using the acquired batch). Then simulate the stopping rule across multiple runs: at what fraction of trials does the system accuracy at τ exceed γ? How sensitive is this to δ? This is the single most impactful improvement the authors could make.
2. **Clarify the RxRx3 status.** Either present the RxRx3 results (even if negative, with analysis of why the method underperformed) or remove the detailed setup description to avoid misleading the reader.
3. **Add a brief limitations paragraph** discussing when weak calibration may break (early rounds, poor initialization) and the computational cost of retraining from scratch.

---

## Score and Decision

The paper makes a clear, well-motivated conceptual contribution (inference set design) and provides strong empirical support for the core mechanism across diverse settings (MNIST, QM9, industrial-scale phenomics). The weaknesses are addressable: the stopping criterion validation is a genuine gap but does not invalidate the paper's central insight, and the RxRx3 coherence issue is a presentation fix. The paper is above the acceptance threshold for a strong venue.

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>